Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas

被引:642
作者
Smith, JS
Perry, A
Borell, TJ
Lee, HK
O'Fallon, J
Hosek, SM
Kimmel, D
Yates, A
Burger, PC
Scheithauer, BW
Jenkins, RB
机构
[1] Mayo Clin & Mayo Fdn, Dept Neurol, Div Lab Genet, Div Anat Pathol, Rochester, MN USA
[2] Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[4] Ohio State Univ, Div Neuropathol, Columbus, OH 43210 USA
[5] Washington Univ, Sch Med, St Louis, MO USA
关键词
D O I
10.1200/JCO.2000.18.3.636
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A recent report suggests that alterations of chromosome arms 1p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas. Patients and Methods: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors. Results: The oligodendroglial phenotype was highly associated with loss of 1p (P = .0002), loss of 19q (P < .0001), and combined loss of Ip and 19q (P < .0001). univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log-rank, P = .03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P < .01). This favorable association wets not evident in patients with astrocytoma or mixed oligoastrocytoma. Conclusion: Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management. J Clin Oncol 18:636-645. (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:636 / 645
页数:10
相关论文
共 41 条
[1]  
[Anonymous], 1987, Cancer Cytogenetics
[2]   CHROMOSOME-1 ABERRATIONS IN CANCER [J].
ATKIN, NB .
CANCER GENETICS AND CYTOGENETICS, 1986, 21 (04) :279-285
[3]  
BELLO MJ, 1995, INT J CANCER, V64, P207
[4]   CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA [J].
CAIRNCROSS, G ;
MACDONALD, D ;
LUDWIN, S ;
LEE, D ;
CASCINO, T ;
BUCKNER, J ;
FULTON, D ;
DROPCHO, E ;
STEWART, D ;
SCHOLD, C ;
WAINMAN, N ;
EISENHAUER, E .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2013-2021
[5]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[6]   SUCCESSFUL CHEMOTHERAPY FOR RECURRENT MALIGNANT OLIGODENDROGLIOMA [J].
CAIRNCROSS, JG ;
MACDONALD, DR .
ANNALS OF NEUROLOGY, 1988, 23 (04) :360-364
[7]   The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas [J].
Chou, D ;
Miyashita, T ;
Mohrenweiser, HW ;
Ueki, K ;
Kastury, K ;
Druck, T ;
vonDeimling, A ;
Huebner, K ;
Reed, JC ;
Louis, DN .
CANCER GENETICS AND CYTOGENETICS, 1996, 88 (02) :136-140
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]   PHASE-III COMPARATIVE-EVALUATION OF PCNU AND CARMUSTINE COMBINED WITH RADIATION-THERAPY FOR HIGH-GRADE GLIOMA [J].
DINAPOLI, RP ;
BROWN, LD ;
ARUSELL, RM ;
EARLE, JD ;
OFALLON, JR ;
BUCKNER, JC ;
SCHEITHAUER, BW ;
KROOK, JE ;
TSCHETTER, LK ;
MAIER, JA ;
PFEIFLE, DM ;
GESME, DH .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1316-1321
[10]  
Ferrario M, 1997, QUAL LIFE RES, V6, P56